{"brief_title": "AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer", "brief_summary": "The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.", "condition": "Osteopenia", "intervention_type": "Drug", "intervention_name": "AMG 162 / Denosumab", "description": "60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months", "arm_group_label": "AMG 162 / Denosumab", "criteria": "- Histologically or cytologically confirmed adenocarcinoma of the breast - Subjects with early stage disease who are estrogen receptor positive and who have completed their treatment pathway (surgery, chemo-therapy, radiation, and/or hormone therapy) and are currently on or will initiate aromatase inhibitor therapy, and are expected to stay on aromatase inhibitor therapy for the duration of the 24-month study - All treatment pathway must be completed \u2265 4 weeks prior to study entry, and all acute toxic effect of any above therapy must be resolved to \u2264 Grade 1 by National Cancer Institution (NCI) Common Terminology Criteria for Adverse Events (CTCAE) - Female > 18 years of age - ECOG Performance status 0 and 1 - Lumbar spine, total hip or femoral neck BMD equivalent to a t-score classification of -1.0 to -2.5 - Subject is willing and able to provide signed consent before any study-specific procedure Other criteria also apply.", "gender": "Female", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00089661.xml"}